Emergency Medicine Cases – Where the Experts Keep You in the Know. For complete episodes please visit emergencymedicinecases.com
William G. Wierda, MD, PhD - New Standards for CLL Care With BTK Inhibitors: Using Evidence to Make Personalized Treatment Choices
Manage episode 297564122 series 103624
By PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Go online to PeerView.com/SYN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView Seminar and Tumor Board activity, CLL experts discuss how BTK inhibitors are changing the treatment landscape for patients with CLL. Find out how these experts make treatment choices for upfront and relapsed disease, factoring safety into the decision to use BTK inhibitors and sequencing strategies. These clinical conversations are supported by scientific seminars designed to reinforce the lessons of recent, relevant evidence and by discussions on the integration of BTK inhibitors in a range of CLL patient populations and treatment settings. Upon completion of this accredited CE activity, participants should be better able to: Cite the selectivity and safety profiles of first- and second-generation BTK inhibitors available for use in CLL, Discuss safety and efficacy evidence related to the use of BTK inhibitors as single-agent or combination regimens in treatment-naive and relapsed CLL, and in the setting of BTK inhibitor intolerance, Select single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL based on prognostic features, safety profiles, and therapeutic history, Manage the unique spectrum of adverse events associated with the use of BTK inhibitors in patients with CLL.